MedTrace Logo

Trial of Screening for ALOA-IgG AtheroAbzyme Test

NCT01272986 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-03-08

No results posted yet for this study

Summary

This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.

Conditions

  • Myocardial Ischemia
  • Acute Coronary Syndrome

Interventions

DEVICE

ALOA IgG-Elisa

measurement of IgG Level in blood

DEVICE

ALOA IgG-AtheroAbzyme

measurement of IgG in blood

Sponsors & Collaborators

  • Omicron Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Malek Mohamad · Bahman Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272986 on ClinicalTrials.gov